Public Notice of the Draft Environmental Impact Assessment for the Demonstration Project on the Multi-Functional, Intelligent, Safe, Green, and High-End Transformation of Active Pharmaceutical Ingredients at Wuhan Zhongyou Pharmaceutical Co., Ltd., as well as the Construction of a Pilot-Scale Service Platform
Category: Company News
Release Date: 2020-08-26
Summary:
|
Wuhan Zhongyou Pharmaceutical Co., Ltd. has entrusted Wuhan Yuanqing Environmental Control Technology Co., Ltd. with the environmental impact assessment for the “Demonstration Project on the Transformation of Active Pharmaceutical Ingredients toward Multi-functionality, Intelligentization, Safety, Greenness, and High-End Development, as well as the Construction of a Pilot-Scale Service Platform.” In accordance with the Measures for Public Participation in Environmental Impact Assessment, upon completion of the draft environmental impact report, the public is hereby notified and the contents of the EIA are made available for review, with the aim of soliciting opinions relevant to the project’s environmental impacts. As the project progresses and the EIA work unfolds, the relevant information will be refined or adjusted accordingly. I. Online link to the full text of the Environmental Impact Report (Draft for Public Comments) and methods and channels for consulting the hard copy of the report Full text of the draft for public comment: http://www.qrpharma.net/ 。 Methods and channels for reviewing the paper report: Starting from the date of public notice, the public may review the paper report at the project proponent, Wuhan Zhongyou Pharmaceutical Co., Ltd., located at Chuangye Avenue, Gedian Economic Development Zone. 28 Number. II. Scope of the Public Consultation The primary purpose is to solicit public opinions and suggestions on environmental protection aspects related to the project’s construction. The scope of the public consultation includes the views of relevant entities, experts, citizens, legal persons, and other organizations that are affected by the project and whose environmental rights and interests are directly at stake. Opinions or requests pertaining to land acquisition and relocation, property matters, employment, and other issues unrelated to the project’s environmental impact assessment are not within the scope of the public consultation. III. Online Link to the Public Opinion Form Online link to the public comment form: https://share.weiyun.com/5fSGySMa 。 IV. Methods and Channels for Public Submission of Comments, and the Start and End Dates The public may download the Public Comments Form, print it out, and complete it with suggestions and comments regarding the environmental impacts of this project and the associated environmental protection measures. The completed form should be submitted to Wuhan Zhongyou Pharmaceutical Co., Ltd. Contact information is as follows: Construction Entity: Wuhan Zhongyou Pharmaceutical Co., Ltd. Address: Chuangye Avenue, Gedian Economic Development Zone 28 Number Contact: Zhang Hanbo Contact phone number: 18062602768 V. Period for Public Submission of Comments Please contact the project construction entity within ten working days following this public notice to provide your feedback. |
Keywords: Public Notice of the Draft Environmental Impact Assessment for the Demonstration Project on the Multi-Functional, Intelligent, Safe, Green, and High-End Transformation of Active Pharmaceutical Ingredients at Wuhan Zhongyou Pharmaceutical Co., Ltd., as well as the Construction of a Pilot-Scale Service Platform
Related News Centers
Academic Column
Development History
-
2019
Release time:2023-01-05
-
2018
Release time:2023-01-05
-
2017
Release time:2023-01-05
-
2014
Release time:2023-01-05
-
2013
Release time:2023-01-05
-
2012
Release time:2023-01-05
-
2011
Release time:2023-01-05
-
2010
Release time:2023-01-05
-
2009
Release time:2023-01-05
-
2008
Release time:2023-01-05
-
2007
Release time:2023-01-05
-
2006
Release time:2023-01-05
-
2005
Release time:2023-01-05
-
2004
Release time:2022-12-30
-
2003
Release time:2022-12-30
Branch office
News and Information
-
Qirui Group’s First Innovative Drug, MY008211A Tablets (Lanocapam Hydrochloride Tablets), Successfully Achieves the Primary Efficacy Endpoint in Phase III Clinical Trials
Release time:2026-02-25
-
Qirui Group’s First Innovative Drug Passes Both National Key Inspections on the First Attempt
Release time:2026-01-27
-
Three Employees of Qirui Pharmaceutical Awarded Jiangxia District’s Tangxun Lake Talent Recognition!
Release time:2026-01-15
-
“A ‘Start’ That Stands Out, Bringing in Talented Young Professionals — Qirui Group’s 2026 Campus Recruitment Concludes Successfully”
Release time:2025-12-31
-
Qirui Pharmaceutical’s Ganyining® Ademetionine Disulfonate for Injection Wins Bid in the 11th National Centralized Procurement Round
Release time:2025-11-11
-
Qirui Group Makes Its Debut at the 17th Bio-Industry Conference
Release time:2025-09-08
-
Empowering Your Journey, Illuminating the Path Ahead—Qirui Group’s 2025 New Graduate Onboarding Program Concludes Successfully
Release time:2025-07-23
-
Internationally Accredited! Qirui Technology Earns ACCA Recognized Employer Status
Release time:2025-07-08
-
Safeguarding the Source of Life and Fortifying the Quality Defense Line for Pharmaceutical Water — Professional Training on Purified Water Systems at Qirui Pharmaceutical
Release time:2025-06-05
-
Wuhan Qirui Technology Development Co., Ltd. Donates RMB 100 Million to Huazhong University of Science and Technology
Release time:2025-03-17
-
People-Oriented, Win-Win Future | Qirui Pharmaceutical Honored as “2024 China’s Top Employer”
Release time:2025-02-18
-
Empowering Party Building to Unite New Forces, Achieve Synergy, and Expand “Health”
Release time:2024-07-10
-
Qirui Group Makes Its Debut at CPHI China 2024
Release time:2024-06-28
-
Enhancing Competence Through Competition and Pursuing Development Through Quality: Qirui Pharmaceutical Successfully Holds Its 2024 Annual Quality Knowledge Competition
Release time:2024-06-28
-
Shining with the Light of Wisdom, Passing on the Torch of Scholarship — The Joint Master’s Thesis Defense Ceremony between Qirui Pharmaceutical and China Pharmaceutical University Concludes Successfully
Release time:2024-06-07
-
Academic Gala | The 8th International Forum on Drug-Induced Liver Injury Concludes Successfully; Ornithine Aspartate Recommended in the “Chinese Guidelines for Primary Care Diagnosis and Management of Drug-Induced Liver Injury (2024)”
Release time:2024-05-31
-
Qirui Pharmaceutical Awarded the “Wuhan May Day Labor Medal”
Release time:2024-05-13
-
Qirui Pharmaceutical Selected for Inclusion in the 2023 Jiangxia District List of Proposed Projects for District-Level Technology Transfer and Key R&D Initiatives
Release time:2024-04-12
-
“Made in Wuhan” Generic Drugs Added to the 2020 National Reimbursement Drug List
Release time:2021-03-05
-
Congratulatory Letter to Shandong Ruiyin Bioengineering Co., Ltd.
Release time:2021-02-01
-
Douyin Live Stream Coverage | Qirui’s 2020 Annual Work Summary and Awards Ceremony Held Successfully!
Release time:2021-01-28
-
First Public Notice of the Environmental Impact Assessment for the Demonstration Project on the Transformation and Construction of a Multi-Functional, Intelligent, Safe, Green, and High-End Active Pharmaceutical Ingredient Production Platform and Pilot-Scale Service Platform at Wuhan Zhongyou Pharmaceutical Co., Ltd.
Release time:2020-06-28
-
Decision on Commending the 2020 Pioneers in Epidemic Prevention Responsibility and Model Workers in Resuming Work and Production
Release time:2020-05-11
-
Notice of the Renewal of the Employee Care and Corporate Culture Development Committee
Release time:2020-04-27
Sunshine Avenue, Sunshine Third Road, Miaoshan Subdistrict, Economic Development Zone, Jiangxia District, Wuhan, Hubei Province
QR code
Copyright © Wuhan Qirui Pharmaceutical Co., Ltd. |Privacy Policy
Powered by www.300.cn
This website supports IPv6.